FDA staff: J&J diabetes drug may pose heart risk

Federal drug reviewers think Johnson & Johnson's experimental diabetes drug might bring heart risks because it raised cholesterol levels in patient testing.

In documents just released, Food and Drug Administration staff experts conclude studies showed canagliflozin (kann-AH'glih-floh-zin) slightly increased complications and risk of a urinary tract infection. That's because the pill works by boosting blood sugar excretion via urine.

The studies didn't find other serious problems, such as weakening of bones, damage to the liver or kidneys, or various cancers.

If the FDA approves the New Brunswick, N.J., company's , it would be the first in a new class of Type 2 diabetes medicines, called SGLT2 inhibitors.

Outside advisers to the FDA will review the data during a meeting Thursday and recommend whether the agency should approve canagliflozin.


Explore further

EU OKs Bristol-Myers, AstraZeneca diabetes drug

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: FDA staff: J&J diabetes drug may pose heart risk (2013, January 8) retrieved 25 September 2020 from https://medicalxpress.com/news/2013-01-fda-staff-jj-diabetes-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments